as 12-18-2024 3:35pm EST
GlycoMimetics Inc is a clinical-stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it play in inflammation, cancer, and infection.
Founded: | 2003 | Country: | United States |
Employees: | N/A | City: | ROCKVILLE |
Market Cap: | 19.5M | IPO Year: | 2014 |
Target Price: | $12.00 | AVG Volume (30 days): | 1.2M |
Analyst Decision: | Hold | Number of Analysts: | 3 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.62 | EPS Growth: | N/A |
52 Week Low/High: | $0.14 - $3.53 | Next Earning Date: | 01-06-2025 |
Revenue: | $10,000 | Revenue Growth: | -86.67% |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
GLYC Breaking Stock News: Dive into GLYC Ticker-Specific Updates for Smart Investing
Associated Press Finance
a month ago
PR Newswire
a month ago
Business Wire
a month ago
Simply Wall St.
2 months ago
TipRanks
2 months ago
MT Newswires
2 months ago
Business Wire
2 months ago
Business Wire
2 months ago
The information presented on this page, "GLYC GlycoMimetics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.